Phase II Pethema trial of alternating Bortezomib and Dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez NC, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J. Journal of Clinical Oncology 25(28):4452-8. FI: 17.793 (Q1) Molecular biology of myeloma Gutiérrez NC, García-Sanz R, San Miguel JF. Clinical & Translational Oncology 9(10):618-24. FI: 1.146 (Q4) New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY) Baró C, Salido M, Espinet B, Astier L, Domingo A, Granada I, Millà F, Carrió A, Costa D, Luño E, Hernández JM, Campo E, Florensa L, Ferrer A, Salar A, Bellosillo B, Besses C, Serrano S, Solé F. Leukemia Research 32(5):727-36. FI: 2.358 (Q3) High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients Oriol A, Ribera JM, Bergua J, Giménez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernández Rivas JM, Hoelzer D. Cancer 113(1):117-25. FI: 5.418 (Q1) Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor Herrero AB, Astudillo M, Balboa MA, Cuevas C, Balsinde J, Moreno S. Cancer Research 68(23):9779-87. FI: 7.543 (Q1) Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, Del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F. Haematologica 93(7):1001-8. FI: 6.416 (Q1) Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma Schilling G, Hansen T, Shimoni A, Zabelina T, Simon-Pérez JA, Gutiérrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, Miguel JS, Nagler A, Kröger N. Leukemia 22(6):1250-5. FI: 8.296 (Q1) BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia José-Enériz ES, Román-Gómez J, Cordeu L, Ballestar E, Gárate L, Andreu EJ, Isidro I, Guruceaga E, Jiménez-Velasco A, Heiniger A, Torres A, Calasanz MJ, Esteller M, Gutiérrez NC, Rubio A, Pérez-Roger I, Agirre X, Prósper F. British Journal of Haematology 142(4):571-82. FI: 4.597 (Q1) An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in Leukemia study prephase Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, Gilkes AF, Hofmann WK, Basso G, Dell'orto MC, Foà R, Chiaretti S, De Vos J, Rauhut S, Papenhausen PR, Hernández JM, Lumbreras E, Yeoh AE, Koay ES, Li R, Liu WM, Williams PM, Wieczorek L, Haferlach T. British Journal of Haematology 142: 802-7. FI: 4.597 (Q1) The P2Y14 receptor activity in glioma C6 cells Krzemiska P, Pomorski P, Baraska J. European Journal of Pharmacology 594(1-3):49-54. FI: 2.585 (Q2)
|
